Start-ups that fit the criteria of being at pre-clinical research or MVP-stage in reproductive health and fertility are invited to take part in the selection. Focus areas include development of new peptides, new delivery systems, genetics and genomics, as well as new diagnostic instruments and big data solutions.
Participants will get feedback from acknowledged experts in the field and a chance to get internships and access to Ferring research labs all over the world to accelerate their product development. The most promising projects will be invited to discuss long-term opportunities for partnership with Ferring.
Participation is free of any charges. Get more information and submit application till September 16, 2019 ferring.generation-startup.ru/en/
GenerationS is the Federal corporate platform to develop acceleration tools. It has been held by RVC since 2013. To date, the accelerator infrastructure includes more than 14,000 startups from 30 countries, 400 corporate and ecosystem partners. GenerationS has become the first Russian accelerator included in the Global Accelerator Network (GAN), created by Techstars.
Ferring Pharmaceuticals is a biopharmaceutical company engaged in search, development and implementation of the innovation products in reproductive healthcare, oncology, urology, gastroenterology, endocrinology and orthopaedics. Company research activity and products serve a single purpose - to create specialized medication able to fight various diseases and pathologies, using the human organism’s resources and functional potential. Marketing, medical services, retail and wholesale subdivisions of Ferring work in almost 60 countries, management is done from the headquarters in Saint-Prex, Switzerland.